News: Endologix Inc (ELGX.O)
5.28USD
23 Dec 2009
$0.10 (+1.93%)
$5.18
$5.20
$5.38
$5.18
86,937
329,090
$6.27
$0.97
Fri, Oct 9 2009
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 9
NEW YORK, Oct 9 (Reuters) - Some U.S. stocks on the move on Friday:
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 9
(Updates to after the open, adds Citigroup/Occidental, AK Steel, Sunrise, Acorda, MDS, Kimberly Clark/I-Flow, Scientific Learning)
UPDATE 1-Endologix raises 2009 rev view
March 23 (Reuters) - Medical device maker Endologix Inc raised its 2009 revenue view and forecast first-quarter revenue above market estimates on better-than-expected adoption of its recently approved delivery system, IntuiTrak.
UPDATE 1-Endologix says gets unsolicited bid from hedge fund
(Recasts; adds details, background) Oct 15 (Reuters) - Endologix Inc said it received an unsolicited takeover bid from hedge fund Elliott Associates LP for $2.25 a share, 18 percent higher than the stock's Wednesday closing price.
BRIEF-Endologix sees total 2007 revenue of $27.8 mln
Jan 7 (Reuters) - ENDOLOGIX INC : * Endologix expects total 2007 revenue of $27.8 million * Forecasts fourth quarter revenue about $8 million * Forecasts 2008 product revenue $39 million to $43 million * Forecasts 2008 gross margin to range from 71 percent to 75 percent * Forecasts 2008 total operating expenses $35- $39 million * Reuters Estimates fiscal year 2007 revenue view $27.48 mln
TABLE-Endologix Q2 net loss narrows
ENDOLOGIX INC. (in $) Latest Yr-ago qtr Loss/shr (diluted) 0.09 0.11 Net loss (million) 3.7 4.4 Total revenue (million) 6.3 3.5 Reuters Estimates: Loss/shr $0.10, revenue $6.6 million. (Reporting by Aditi Samajpati in Bangalore)
Press Releases
- Endologix Appoints Dan Lemaitre to its Board of Directors
- Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
- Endologix Receives IDE Approval for Fully Percutaneous Approach to EVAR
- Endologix to Present at Three Upcoming Conferences
- Endologix Reports 47% Third Quarter 2009 Revenue Growth





